On Friday (7/30/10), GERN said the clinical hold on its application has been lifted. The FDA notification enables Geron to move forward with the world’s first clinical trial of a human embryonic stem cell (hESC)-based therapy in man. Read more…
For Q2/10, GERN reported a net loss of $17 M, or $(0.18) per share. Read more…
It’s a huge challenge: skin must be waterproof, flexible and a barrier against infection. Both the cells that make up the outermost layer of the skin and the structure of how the cells fit with each other must be duplicated. So far, no one has figured out how to synthetically make our body’s largest organ. Read more…
PureGraft™ and Celution® approvals in the EU allows CYTX to offer Read more…
CYTX has received European (CE Mark) approval for the PureGraft™ 250/PURE System for autologous fat grafting procedures, Read more…
ATHX announced positive (7/28/10) results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), Read more…
ISCO.OB’s Lifeline Cell Technology® (Lifeline) and Sristi Biosciences have entered into a distribution agreement for the Lifeline® brand of human cell culture products in India. Read more…
The July 25-29 AACC (American Association of Clinical Chemistry) Meeting in Anaheim will have close to 20,000 clinical lab professionals and over 500 exhibitors. A stock rally in the sector was ignited last week by earnings announcements Read more…
ACTC.OB has submitted documentation and a complete response to substantively address the issues raised by the FDA in connection with their plans to initiate a Phase I/II multicenter study using embryonic stem (ES) cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD). Read more…
CYTX received expanded European approval (CE Mark) for its Celution® System, Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.